Abstract
Neprilysin inhibitors augment the natriuretic peptide system by preventing the breakdown of atrial natriuretic peptide and B-type natriuretic peptide. LCZ696, an angiotensin receptor neprilysin inhibitor composed of a neprilysin inhibitor prodrug and the angiotensin receptor antagonist valsartan, has proven effective in hypertension, has shown promise in a pilot trial of heart failure with preserved ejection fraction, and is being tested in a large outcomes trial of heart failure with reduced ejection fraction. A preserved ejection fraction outcomes trial is beginning.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aminobutyrates / therapeutic use*
-
Angiotensin Receptor Antagonists / therapeutic use*
-
Biphenyl Compounds
-
Drug Combinations
-
Heart Failure / drug therapy*
-
Heart Failure / physiopathology
-
Humans
-
Models, Biological
-
Neprilysin / antagonists & inhibitors*
-
Stroke Volume / drug effects
-
Stroke Volume / physiology
-
Tetrazoles / therapeutic use*
-
Valsartan
Substances
-
Aminobutyrates
-
Angiotensin Receptor Antagonists
-
Biphenyl Compounds
-
Drug Combinations
-
Tetrazoles
-
Valsartan
-
Neprilysin
-
sacubitril and valsartan sodium hydrate drug combination